Scarica l'app Stockscreener
8.94
3.14%
-0.29
Dopo l'orario di chiusura:
8.95
0.010
+0.11%
Panoramica
Notizia
Cronologia dei prezzi
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Crescent Biopharma Inc Borsa (CBIO) Ultime notizie
Is Crescent Biopharma Inc. (GKO0) stock in buy zone after pullback2025 Technical Patterns & Weekly High Return Forecasts - mfd.ru
CBIO: Global oncology pipeline advances with CR-001 and ADCs, backed by strong funding and partnerships - TradingView
FMR LLC's Strategic Acquisition of Crescent Biopharma Inc Shares - GuruFocus
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Crescent Biopharma (CBIO) Price Target Increased by 10.69% to 29.92 - Nasdaq
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Crescent Biopharma Announces Grants of Inducement Awards - Sahm
Crescent Biopharma (NASDAQ:CBIO) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded to "Strong-Buy" at Piper Sandler - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded at Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Guggenheim to Strong-Buy Rating - MarketBeat
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Initiates Crescent Biopharma(CBIO.US) With Buy Rating, Announces Target Price $35 - 富途资讯
Guggenheim initiates coverage on Crescent Biopharma with 'buy' - TradingView
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage - TipRanks
The deal that sent Crescent Biopharma shares surging over 40% pre-market today - MSN
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Crescent and Kelun announce IND approvals for CR-001, CR-003 - BioWorld MedTech
Crescent Biopharma Secures IND Clearances For Two Novel Oncology Candidates - Nasdaq
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA - BioSpace
FDA clears Crescent’s CR-001 IND for solid tumor treatment By Investing.com - Investing.com South Africa
FDA clears Crescent’s CR-001 IND for solid tumor treatment - Investing.com
Two experimental cancer drugs cleared to begin human trials in U.S., China - Stock Titan
Crescent Biopharma, Inc. (CBIO) - MSN
Crescent Biopharma (CBIO) Stock Analysis Report | Financials & Insights - Benzinga
Crescent Biopharma price target raised to $32 from $28 at Stifel - MSN
Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Can Crescent Biopharma Inc. (GKO0) stock sustain free cash flowWeekly Stock Recap & Trade Opportunity Analysis - Улправда
Is Crescent Biopharma Inc. (GKO0) stock dividend growth reliable2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда
Crescent Biopharma (CBIO) insider reports RSU and option awards - Stock Titan
Brokerages Set Crescent Biopharma, Inc. (NASDAQ:CBIO) Target Price at $26.40 - Defense World
Huge insider buying in MGM and Salesforce - MSN
Frazier Life Sciences Management L.P. Takes Position in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
CBIO Insider Trading - Quiver Quantitative
GlycoMimetics executives to depart amid merger plans - MSN
BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Braidwell LP Invests $4.22 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (CBIO) Stock News & Articles - 24/7 Wall St.
Huge Insider Buying in MGM and Salesforce - 24/7 Wall St.
Crescent Biopharma (NASDAQ:CBIO) Director Fairmount Funds Management Llc Purchases 1,360,000 Shares of Stock - Defense World
Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific - BioWorld MedTech
Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock - MarketBeat
Shareholder Fairmount Funds Management LLC Buys 1,360,000 ($18.2M) Of Crescent Biopharma Inc [CBIO] - TradingView — Track All Markets
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership - Indian Pharma Post
Sichuan Kelun-Biotech partners with Crescent Biopharma for oncology advancements - MSN
Affinity Asset Advisors LLC Makes New $4.52 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma - Reuters
Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):